Hilliard Brandon K, Prendergast Jessica E, Smith Mia J
Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Biomolecules. 2025 Feb 25;15(3):332. doi: 10.3390/biom15030332.
Type 1 diabetes (T1D) is an autoimmune disease that affects an estimated 30 million people worldwide and results in a lifelong dependency of exogenous insulin treatments. While T1D is characterized by T-cell driven-destruction of the insulin-secreting β cells, B lymphocytes play a key role in the islet-immune interface. B cells are an essential intermediary between islet cells and other immune-cell populations. Through antigen presentation, cytokine secretion, and antibody production, B cells play a role in activating autoreactive islet-specific T cells, thus potentiating pancreatic inflammation in the early stages of T1D. Despite this, their role in disease development remains an understudied feature of T1D with significant therapeutic potential. Herein, we will discuss the current knowledge of the islet-immune-cell interface within T1D through the lens of B lymphocytes. We will also consider knowledge gaps that may be limiting further therapeutic opportunities.
1型糖尿病（T1D）是一种自身免疫性疾病，全球约有3000万人受其影响，患者终生依赖外源性胰岛素治疗。虽然T1D的特征是T细胞驱动胰岛素分泌β细胞的破坏，但B淋巴细胞在胰岛免疫界面中起关键作用。B细胞是胰岛细胞与其他免疫细胞群体之间的重要中介。通过抗原呈递、细胞因子分泌和抗体产生，B细胞在激活自身反应性胰岛特异性T细胞中发挥作用，从而在T1D早期加剧胰腺炎症。尽管如此，它们在疾病发展中的作用仍是T1D中一个研究不足但具有巨大治疗潜力的特征。在此，我们将通过B淋巴细胞的视角讨论目前关于T1D中胰岛免疫细胞界面的知识。我们还将考虑可能限制进一步治疗机会的知识空白。
